Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery

Drug Delivery

Volumn 18, Issue 6, 2011, Pages 441-450

  Dong, Zhao ^a   Xie, Shuyu ^a   Zhu, Luyan ^a   Wang, Yan ^a   Wang, Xiaofang ^a   Zhou, Wenzhong ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

antibacterial activity; bioavailability; Norfloxacin; solid lipid nanoparticles; sustained release

Indexed keywords

NORFLOXACIN; POLYVINYL ALCOHOL; SOLID LIPID NANOPARTICLE; STEARIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERICIDAL ACTIVITY; BROTH DILUTION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENCAPSULATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARAMETER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; TECHNIQUE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; LIPIDS; MALE; NANOPARTICLES; NORFLOXACIN; PARTICLE SIZE; POLYVINYL ALCOHOL; RATS; RATS, SPRAGUE-DAWLEY; STEARIC ACIDS; SURFACE-ACTIVE AGENTS;

EID: 79960686477     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2011.577109     Document Type: Article

References (66)

1. Aleem O, Kucheka B, Pore Y, Late S. (2008). Effect of β-cyclodextrin and hydroxypropyl β-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J Pharm Biomed Anal. 47, 535-540.
2. Andersson MI, MacGowan AP. (2003). Development of the quinolones. J Antimicrob Chemother. 5, 1-11. (Pubitemid 36622099)
3. Arredondo GJL, Figueroa DR, Rosas A. (2004). Comparison of short-term treatment regimen of ciprofloxacin versus longterm treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J Antimicrob Chemother. 54, 840-843. (Pubitemid 39386743)
4. Bala I, Hariharan S, Kumar MN. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carr Syst. 21, 387-422. (Pubitemid 41647578)
5. Beaulac C, Clément-Major S, Hawari J, Lagacé J. (1996). Eradication of mucoid Pseudomonas aeruginosa with uid liposomeencapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemo-ther. 40, 665-669.
6. Beaulac C, Sachetelli S, Laglce J. (1998). In-vitro bactericidal efficacy of sub-MIC concentration of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria. J Antimicrob Chemother. 41, 35-41. (Pubitemid 28064248)
7. Bhardwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R, Kumar MNV. (2005). Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J Biomed Nanotechnol. 1, 235-258.
8. Boerema JB, Saene HKV. (1986). Norfloxacin treatment in complicated urinary tract infection, Scand. J Infect Dis. Suppl. 48, 20-26. (Pubitemid 16025670)
9. Breda SA, Jimenez-Kairuz AF, Manzo RH, Olivera ME. (2009). Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives, Int J Pharm. 371, 106-113.
10. Brown SA. (1996). Fluoroquinolones in animal health. J Vet Pharmacol Therap. 19, 1-14. (Pubitemid 26096341)
11. Carratalá J, Fernández-Sevilla A, Tubau FE, Callis M, Gudiol F. (1995). Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin, Clin Infect Dis. 20, 557-560.
12. Carratala J, Roson B, Fernandez-Sevilla A, Alcaide F, Gudiol F. (1998). Bacteremic pneumonia in neutropenic patients with cancer causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 158, 868-872. (Pubitemid 28183641)
13. Charman WN. (2000). Lipids, lipophilic drugs, and oral drug delivery- some emerging concepts. J Pharm Sci. 89, 967-978.
14. Davda J, Labhasetwar V. (2002). Characterization of nanoparticle uptake by endothelial cells. Int J Pharm. 233, 51-59. (Pubitemid 34230418)
15. Desai MP, Labhasetwar V, Amidon GL, Levy RJ. (1996). Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res. 13, 1838-1845. (Pubitemid 27034116)
16. Eandi M, Viano I, Nola FD, Leone L, Genazzani E (1983). Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage. Eur. J. Clin. Microbiol. 2, 253-259. (Pubitemid 13010462)
17. Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, Samadi N, Atyabi F, Dinarvaand R. (2007). Preparation and antibacterial activity evaluation of rifampicin-loaded poly-lactide-co-glycolide nanoparticles. Nanomedicine Nanotechnology, Biology and Medicine. 3, 161-167. (Pubitemid 46908907)
18. Fernández J, Arbol LR, Gómez C. (2006). Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 131, 1049-1056. (Pubitemid 44498687)
19. Ferrero L, Cameron B, Crouzet J. (1995). Analysis of gyrA and gyrB mutations in stepwise-selected ciprofloxacin-resistant mutants of staphylococcus aureus. Antimicrob Agents Chemother. 39, 1554-1558.
20. Gao F, Yang P, Xie, J Wang HF. (1995). Synthesis, characterization and antibacterial activity of novel Fe(III), Co(II), and Zn(II) complexes with norfloxacin. J Inorg Biochem. 60, 61-67.
21. Garcia-Fuentes M, Torres D, Alonso MJ. (2002). Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules. Colloids Surf B: Biointerfaces. 27, 159-168.
22. Gips M, Soback, S. (1996). Norfloxacin nicotinate pharmacokinetics in unwearied and weaned calves. J Vet Pharmacol Ther. 19, 130-134. (Pubitemid 26161833)
23. Guyot M, Fawaz F, Bildet J, Bonini FAM, Lagueny. (1995). Physicochemical characterization and dissolution of norfloxacin cyclodextrin inclusion compounds and PEG solid dispersions. Int J Pharm. 123, 53-63.
24. Han C, Qi CM, Zhao BK, Cao J, Xie SY, Wang S, Zhou WZ. (2009). Hydrogenated castor oil nanoparticles as carriers for the subcutaneous administration of tilmicosin: in vitro and in vivo studies. J Vet Pharmacol Ther. 32, 116-123.
25. Han YX, Wu X, Yang JH, Sun SN. (2005). The fluorescence characteristic of the yttrium-norfloxacin system and its analytical application, J Pharm Biomed Anal, 38, 528-531. (Pubitemid 40733191)
26. Hans H, Li SG. (1991). Norfloxacin, next term the first of a new class of fluoroquinolone antimicrobials, revisited. Int J Antimicrob Agents. 1, 3-28.
27. Hooper DC, Wolfson JS. (1985). The Fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother. 28, 716-721. (Pubitemid 16215549)
28. Hou LL, Zhao XB, Ma YK, Zhai GX, Li LB, Lou HX. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Controlled Release. 133, 238-244.
29. Hu FQ, Yuan H, Zhang HH, Fang M. (2002). Preparation of solid lipid nanoparticles with clobetasol propionate by a novel solvent diffusion method in aqueous system and physicochemical characterization-selected. Int J Pharm. 239, 121-128. (Pubitemid 34615801)
30. Hussain N, Jaitley V, Alexander TF. (2001). Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv Drug Deliv Rev. 50, 107-142. (Pubitemid 32727279)
31. Jani PU, McCarthy DE, Florence AT. (1992). Nanosphere and microsphere uptake via Peyers patches: observation of the rate of uptake in rat after a single oral dose. Int J Pharm. 86, 239-246.
32. Jenninga V, Schäfer-Kortingb M, Gohla S. (2000). Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Controlled Release. 66, 115-126. (Pubitemid 30160850)
33. Kalaria DR, Sharma G, Beniwal V, Kumar MNVR. (2008). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 26, 492-501.
34. Lavy E, Ziv G, Glickman A. (1995). Intravenous disposition kinetics, oral and intramuscular bioavailability and urinary excretion of norfloxacin nicotinate in donkeys. J Vet Pharmacol Ther. 18, 101-107.
35. Levy MY, Schutze W, Fuhrer C, Benita S. (1994). Characterization of diazepam submicron emulsion interface: role of oleic acid, J Microencapsul. 11, 79-92. (Pubitemid 24030965)
36. Li HL, Zhao XB, Ma YK, Zhai GX, Li LB, Lou HX. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Controlled Release. 133, 238-244.
37. Li XF, Carter SJ, Dovichi NJ. (2000). Non-aqueous capillary electrophoresis of tamoxifen and its acid hydrolysis products, J Chromatogra A. 895, 81-85.
38. Luo YF, Chen DW, Ren LX, Zhao XL, Qin J. (2006). Solid lipid nanoparticles for enhancing vinpocetines oral bioavailability. J Controlled Release. 114, 53-59. (Pubitemid 44144503)
39. Kaplowitz L, Vishniavsky N, Evans T. (1987). Norfloxacin in the treatment of uncomplicated gonococcal infections. Am J Med, 82, 35-39.
40. Maeda H. (2001). The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 41, 189-207.
41. Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Controlled Release. 107, 215-228. (Pubitemid 41319672)
42. Misra R, Acharya S, Dilnawaz F, Sahoo SK. (2009). Sustained antibacterial activity of doxycycline-loaded poly(D,L-lactide-coglycolide) and poly(e-caprolactone) nanoparticles. Nanomedicine. 4, 519-530.
43. Mühlen AZ, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism, Eur J Pharm Biopharm. 45, 149-155. (Pubitemid 28167741)
44. Müller RH, Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 113, 151-170. (Pubitemid 39237077)
45. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art, Eur J Pharm Biopharm. 50, 161-177. (Pubitemid 30326695)
46. Munoz A, Guichard JP, Reginault P. (1994). Micronised fenofibrate. Atherosclerosis. 110, 45-48.
47. Nordskog BK, Phan CT, Nutting DF. (2001). An examination of the factors affecting intestinal lymphatic transport of dietary lipids. Adv Drug Deliv Rev. 50, 21-44. (Pubitemid 32727275)
48. Pandey R, Khuller GK (2005). Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis. 85, 227-234. (Pubitemid 40805619)
49. Pandey R, Sharma S, Khuller GK (2005). Oral solid lipid nanoparticlebased antitubercular chemotherapy. Tuberculosis. 85,415-420. (Pubitemid 41617396)
50. Panyam J, Labhasetwar V. (2003). Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Del Rev. 55, 329-347. (Pubitemid 36297053)
51. Pittman W, Moon JO, Hamrick LC, Cox CE, Clark J, Childs S, Pizzuti D, Fredericks J, Clair PS. (1993). Randomized double-blind trial of high-and low-dose fleroxacin versus norfloxacin for complicated urinary tract infection. Am J Med. 94, 101-104.
52. Porter CJH, Charman WN. (2001). In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev. 50, 127-147.
53. Preheim LC, Cuevas TA, Roccaforte JS, Mellencamp MA, Bittner MJ. (1987). Oral use of ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim sulfamethoxazole-resistant bacteria, Amer J Med. 82, 295-297.
54. Sachetelli S, Khalil H, Chen T, Beaulac C, Sénéchal S, Lagacé J. (2000). Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta. 1463, 254-266. (Pubitemid 30081785)
55. Smith CR. (1987). The adverse effects of fluoroquinolones, J Antimicrob Chemoth. 19, 709-712
56. Ner M. (2006). Preparation, characterization and physico-chemical properties of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): Their benefits as colloidal drug carrier systems.Pharmazie. 61,375-386 (Pubitemid 43724410)
57. Vasir JK, Tambwekar K, Garg S. (2003). Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm. 255, 13-32. (Pubitemid 36369587)
58. Verhoef J, Rozenberg-Arska M. (1989). Prevention of bacterial and fungal infections in granulocytopenic patients. Eur J Cancer. 25, 1345-1350. (Pubitemid 19234454)
59. Wella M, Nabera KG, Kinzig-Schippersb M, Sörgelb F (1998). Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose. Int J Antimicrob Ag. 10, 31-38.
60. Wolfson JS, Hooper DC. (1988). Norfloxacin: a new targeted fluoroquinolone antimicrobial agent. Ann Intern Med. 108, 238-251. (Pubitemid 18081199)
61. Xie SY, Pan BL, Wang M, Zhu LY, Wang FH, Dong Z, , Wang XF, Zhou WZ.(2010). Formulation, characterization and pharmacokinetics of praziquantel-loaded hydrogenated castor oil-solid lipid nanoparticles, Nanomedicine.5, 693-701
62. Xie SY, Wang SL, Zhao BK, Han C, Wang M, Zhou WZ. (2008). Effect of PLGA as a polymeric emulsifier on preparation of hydrophilic protein-loaded solid lipid nanoparticles. Colloids Surf B: Biointerfaces. 67, 199-204.
63. Xie SY, Wang SL, Zhu LY, Wang FH, Zhou WZ. (2009). The effect of glycolic acid monomer ratio on the emulsifying activity of PLGA in preparation of protein-loaded SLN. Colloids Surf B: Biointerfaces. 74, 358-361
64. Yuan H, Chen J, Du YZ, Hu FQ, Zeng S, Zhao HL. (2007). Studies on oral absorption of stearic acid SLN by a novel fluorometric method. Colloids Surf B: Biointerface. 58,157-164. (Pubitemid 46921452)
65. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. (2008). Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther. 83, 761-769. (Pubitemid 351556021)
66. Zhang Q, Yie GQ, Li Y, Yang Q, Nagai T. (2000). Studies on the cyclosporin a loaded stearic acid nanoparticles. Int J Pharm. 200, 153-159. (Pubitemid 30364902)